Critical Drugs for Critical Care: Protecting the US Pharmaceutical Supply in a Time of Crisis.
作者信息
Socal Mariana P, Sharfstein Joshua M, Greene Jeremy A
机构信息
Mariana P. Socal and Joshua M. Sharfstein are with the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Jeremy A. Greene is with the Department of History of Medicine and the Center for Medical Humanities and Social Medicine, Johns Hopkins University School of Medicine.
出版信息
Am J Public Health. 2020 Sep;110(9):1346-1347. doi: 10.2105/AJPH.2020.305803.
Abstract
摘要
相似文献
1
Critical Drugs for Critical Care: Protecting the US Pharmaceutical Supply in a Time of Crisis.重症监护的关键药物：在危机时刻保护美国药品供应
Am J Public Health. 2020 Sep;110(9):1346-1347. doi: 10.2105/AJPH.2020.305803.
2
China's Coronavirus-Induced Paralysis Threatens U.S. Drug Supply Chain.中国因新冠病毒导致的瘫痪威胁美国药品供应链。
Mo Med. 2020 Mar-Apr;117(2):86-88.
3
COVID-19 and Drug Shortages: A Call to Action.COVID-19 与药品短缺：行动呼吁。
J Manag Care Spec Pharm. 2020 Aug;26(8):945-947. doi: 10.18553/jmcp.2020.26.8.945.
4
The coronavirus outbreak could make it quicker and easier to trial drugs.冠状病毒的爆发可能会使药物试验更快、更容易。
Nature. 2020 Jun;582(7811):172. doi: 10.1038/d41586-020-01524-0.
5
Drug Shortages and the Defense Production Act.药品短缺与《国防生产法》。
Am J Public Health. 2020 Oct;110(10):1504-1505. doi: 10.2105/AJPH.2020.305862.
6
Medication Shortages During the COVID-19 Crisis: What We Must Do.新冠疫情危机期间的药品短缺：我们必须采取的措施。
Mayo Clin Proc. 2020 Jun;95(6):1112-1115. doi: 10.1016/j.mayocp.2020.04.001. Epub 2020 Apr 3.
7
Dozens of coronavirus drugs are in development - what happens next?数十种冠状病毒药物正在研发中——接下来会怎样？
Nature. 2020 May;581(7808):247-248. doi: 10.1038/d41586-020-01367-9.
8
All together to Fight COVID-19.众志成城，抗击疫情。
Am J Trop Med Hyg. 2020 Jun;102(6):1181-1183. doi: 10.4269/ajtmh.20-0281.
9
The healthcare and pharmaceutical vulnerability emerging from the new Coronavirus outbreak.新型冠状病毒爆发引发的医疗保健和制药领域的脆弱性。
Eur J Hosp Pharm. 2020 May;27(3):129-130. doi: 10.1136/ejhpharm-2020-002278. Epub 2020 Mar 18.
10
The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world?新冠疫情对全球医疗产品供应的影响：为何印度仿制药对世界至关重要？
F1000Res. 2020 Apr 1;9:225. doi: 10.12688/f1000research.23057.1. eCollection 2020.
引用本文的文献
1
Global Health Commodities Supply Chain in the Era of COVID-19 Pandemic: Challenges, Impacts, and Prospects: A Systematic Review.新冠疫情时代的全球卫生商品供应链：挑战、影响与前景：一项系统综述
J Multidiscip Healthc. 2024 Apr 11;17:1523-1539. doi: 10.2147/JMDH.S448654. eCollection 2024.
2
Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study.COVID-19 大流行期间重症监护药物购买量的变化：一项全球时间序列研究。
Chest. 2021 Dec;160(6):2123-2134. doi: 10.1016/j.chest.2021.08.007. Epub 2021 Aug 11.
3
The Pandemic and the Supply Chain: Gaps in Pharmaceutical Production and Distribution.大流行与供应链：药品生产与分销的差距
Am J Public Health. 2021 Apr;111(4):635-639. doi: 10.2105/AJPH.2020.306138. Epub 2021 Jan 28.
本文引用的文献
1
'Government Patent Use': A Legal Approach To Reducing Drug Spending.“政府专利使用”：降低药品支出的法律途径
Health Aff (Millwood). 2016 May 1;35(5):791-7. doi: 10.1377/hlthaff.2015.1120.
Zotero 插件